# Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

> **NCT00230763** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 396 (actual)

## Conditions studied

- Glaucoma, Primary Open Angle (POAG)
- Ocular Hypertension

## Interventions

- **PROCEDURE:** GSS questionnaire
- **PROCEDURE:** IOP
- **DRUG:** LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- **PROCEDURE:** Visual acuity

## Key facts

- **NCT ID:** NCT00230763
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 396 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230763, "Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00230763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*